These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8801765)

  • 21. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 24. [Current clinical aspects in hemophilia treatment].
    Meili EO
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood safety and the choice of anti-hemophilic factor concentrate.
    Valentino LA; Oza VM
    Pediatr Blood Cancer; 2006 Sep; 47(3):245-54. PubMed ID: 16724312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Firm behavior in the U.S. market for factor VIII: a need for policy?
    Nauenberg E; Sullivan SD
    Soc Sci Med; 1994 Dec; 39(12):1591-603. PubMed ID: 7846556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 infection in haemophilia.
    Madhok R; Forbes CD
    Baillieres Clin Haematol; 1990 Jan; 3(1):79-101. PubMed ID: 2108739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates.
    Meeks SL; Josephson CD
    Curr Opin Hematol; 2006 Nov; 13(6):457-61. PubMed ID: 17053459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibodies against hepatitis C virus in French hemophiliacs].
    Maisonneuve P; Laurian Y; Noël L; Guérois C; Assouvie-Gomez I; Ferrer-Le Coeur F; Verroust F; Couroucé AM; Saint-Paul B
    Rev Fr Transfus Hemobiol; 1990 Oct; 33(5):375-7. PubMed ID: 2177602
    [No Abstract]   [Full Text] [Related]  

  • 37. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
    Goldsmith JC; Kasper CK; Blatt PM; Gomperts ED; Kessler CM; Thompson AR; Herring SW; Novak PL
    Am J Hematol; 1992 Jul; 40(3):210-5. PubMed ID: 1609775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.
    Feldman F; Chandra S; Huang C
    Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the clinical management of haemophilia.
    Bloom AL
    Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hemophilia and acquired immunodeficiency].
    Allain JP
    Rev Prat; 1989 Dec; 39(30):2674-7. PubMed ID: 2515581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.